133059-43-5

Basic information

• Product Name: 4-Bromo-3-fluorobenzaldehyde
• Synonyms: 4-BROMO-3-FLUOROBENZALDEHYDE;4-Bromo-3-fluorobenzaldehyde 98%;4-Bromo-3-fluorobenzaldehyde98%;3-Fluoro-4-bromobenzaldehyde;Benzaldehyde, 4-broMo-3-fluoro-;4-BroMo-3-fluorobenzaldehyde, 95+%;4 - broMine - 3 - fluoro benzaldehyde
• CAS NO: 133059-43-5
• Molecular Formula: C₇H₄BrFO
• Molecular Weight: 203.01
• Product Categories: Aromatic Aldehydes & Derivatives (substituted);Benzaldehyde;Miscellaneous;Aldehydes;Aryl Fluorinated Building Blocks;Building Blocks;C7;Carbonyl Compounds;Chemical Synthesis;Fluorinated Building Blocks;Organic Building Blocks;Organic Fluorinated Building Blocks;Other Fluorinated Organic Building Blocks
• Mol File: 133059-43-5.mol

Chemical Properties

• Melting Point: 55-59℃
• Boiling Point: 240.2 °C at 760 mmHg
• Flash Point: 99.1 °C
• Appearance: /
• Density: 1.67 g/cm³
• Vapor Pressure: 0.0384mmHg at 25°C
• Refractive Index: 1.584
• Storage Temp.: Room temperature.
• Solubility: soluble in Methanol
• CAS DataBase Reference: 4-Bromo-3-fluorobenzaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Bromo-3-fluorobenzaldehyde(133059-43-5)
• EPA Substance Registry System: 4-Bromo-3-fluorobenzaldehyde(133059-43-5)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 36/37/38-36-22
• Safety Statements: 26-36/37/39
• WGK Germany: 3
• Hazardous Substances Data: 133059-43-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-Bromo-3-fluorobenzaldehyde is used as a key intermediate in the synthesis of Deuterated Dihydropyrimidine compounds. These compounds have demonstrated potential as anti-HBV (Hepatitis B Virus) agents, making 4-Bromo-3-fluorobenzaldehyde an essential component in the development of novel treatments for Hepatitis B.
The specific application of 4-Bromo-3-fluorobenzaldehyde in the pharmaceutical industry is due to its ability to be incorporated into the molecular structure of Deuterated Dihydropyrimidine compounds, which have shown promise in combating the Hepatitis B Virus. This makes it a valuable asset in the ongoing efforts to develop effective treatments for this viral infection.

InChI:InChI=1/C7H4BrFO/c8-6-2-1-5(4-10)3-7(6)9/h1-4H

Upstream product

• 201230-82-2 carbon monoxide 
• 136434-77-0 4-bromo-3-fluoroiodobenzene 
• 124-38-9 carbon dioxide 
• 127425-73-4 1-bromo-4-(bromomethyl)-2-fluorobenzene 
• 350587-20-1 1-bromo-4-(dibromomethyl)-2-fluorobenzene 
• 222978-01-0 4-bromo-3-fluorobenzyl alcohol 
• 133059-44-6 4-bromo-3-fluorobenzonitrile 

Downstream Products

• 222978-01-0 4-bromo-3-fluorobenzyl alcohol 
• 939050-73-4 3-fluoro-4-(5-(piperidin-1-yl)benzofuran-2-yl)benzaldehyde 
• 57592-43-5 2-fluoro-1,1'-biphenyl-4-carbaldehyde 
• 1337991-98-6 4-bromo-2-(4-bromo-3-fluorophenyl)-5-ethyltetrahydropyran 
• 1365267-60-2 (Z)-5-(4-bromo-3-fluorobenzylidene)-4-thioxo-thiazolidine-2-one 
• 1173119-94-2 (E)-ethyl 3-(4-bromo-3-fluorophenyl)acrylate 

Related news

Analysis of 4-Bromo-3-fluorobenzaldehyde (cas 133059-43-5) and separation of its regioisomers by one-dimensional and two-dimensional gas chromatography09/02/2019

A starting material, 4-bromo-3-fluorobenzaldehyde, was used for active drug substance (API) AMG 369 production. The presence of the regioisomer impurities in the starting material 4-bromo-3-fluorobenzaldehyde presented significant challenges for the API synthetic route development due to the phy...detailed

Relevant articles and documents

Rhodium-catalyzed reductive carbonylation of aryl iodides to arylaldehydes with syngas

The reductive carbonylation of aryl iodides to aryl aldehydes possesses broad application prospects. We present an efficient and facile Rh-based catalytic system composed of the commercially available Rh salt RhCl3·3H2O, PPh3 as phosphine ligand, and Et3N as the base, for the synthesis of arylaldehydes via the reductive carbonylation of aryl iodides with CO and H2 under relatively mild conditions with a broad substrate range affording the products in good to excellent yields. Systematic investigations were carried out to study the experimental parameters. We explored the optimal ratio of Rh salt and PPh3 ligand, substrate scope, carbonyl source and hydrogen source, and the reaction mechanism. Particularly, a scaled-up experiment indicated that the catalytic method could find valuable applications in industrial productions. The low gas pressure, cheap ligand and low metal dosage could significantly improve the practicability in both chemical researches and industrial applications.

Rhodium-Catalyzed Formylation of Aryl Halides with CO2 and H2

The reductive formylation of aryl iodides/bromides to aryl aldehydes using CO2/H2 is presented for the first time. It was realized over a catalytic system composed of RhI3 or RhI3/Pd(dppp)Cl2 (dppp = 1,3-bis(diphenyphosphino)propane) and PPh3 in the presence of Ac2O/Et3N at 100 °C, affording aromatic aldehydes in good to excellent yields, together with good functional-group tolerance and broad substrate scope. The reaction proceeds through three cascade steps, involving HCOOH formation, CO release, and formylation of aryl halides.

ORTHO AMINOAMIDES FOR THE TREATMENT OF CANCER

Compounds of formula are HDAC inhibitors. These compounds are useful for the treatment of diseases such as cancer in humans or animals.

NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS

This invention relates to novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy.

REVERSIBLE INHIBITORS OF MONOAMINE OXIDASE A AND B

The instant invention relates to compounds of formula I, diagrammed below, wherein R3, E, D and Y are defined in the application, which are useful as reversible inhibitors of monoamine oxidase-B and/or monoamine oxidase-A, and therefore useful to treat or prevent neurological diseases or conditions in mammals, preferably humans.

CATHEPSIN CYSTEINE PROTEASE INHIBITORS

This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.

Inhibitors of prenyl-protein transferase

The present invention is directed to piperazine-containing macrocyclic compounds which inhibit prenylyl-protein transferase, such as farnesyl-protein transferase (FTase), and therefore inhibit the prenylation of the oncogene protein Ras. The invention is

Inhibitors of prenyl-protein transferase

The present invention is directed to azepan-2-one compounds which inhibit prenyl-protein transferase, particularly farnesyl-protein transferase (Ftase), and the prenylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting prenyl-protein transferase and the prenylation of the oncogene protein Ras.

Inhibitors of prenyl-protein transferase

The present invention is directed to compounds which inhibit a prenyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting a prenyl-protein transferase and the prenylation of the oncogene protein Ras.

1,3-dioxane derivatives, methods of preparation and liquid crystal compositions including same

Trans-2-phenyl-5-trans-4'-alkylcyclohexyl-1,3-dioxane derivatives represented by the general formula: STR1 wherein R is a linear alkyl group of 1 to 10 carbon atoms, A is a single covalent bond or a --CH2 CH2 -- group, X is F or CN,